Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results

Συγγραφείς: A. Castagna, V. Spagnuolo, L. Galli, C. Vinci, S. Nozza, E. Carini, A. D'Arminio Monforte, F. Montella, A. Antinori, A. Di Biagio, S. Rusconi, A. Lazzarin, C. Viscoli, A. Parisini, R. Prinapori, F. Mazzotta, S. Lo Caputo, M. Di Pietro, C. Tincati, T. Bini, E. Merlini, M. Puoti, M. Moioli, M. Montella, F. di Sora, A. Ammassari, S. Ottou, R. Cauda, S. di Giambenedetto, M. Galli, M. Franzetti, G. Rizzardini, A. Capetti, F. Cossarini, N. Gianotti, C. Mussini, G. Guaraldi

Πηγή: AIDS. 28:2269-2279

Θεματικοί όροι: Adult, Male, 0301 basic medicine, Drug-Related Side Effects and Adverse Reactions, Anti-HIV Agents, Pyridines, Atazanavir Sulfate, HIV Infections, Simplification, 03 medical and health sciences, Atazanavir/ritonavir, HIV, Nucleos(t)ide reverse transcriptase inhibitors toxicity, Protease inhibitor monotherapy, Virological suppression, Antiretroviral Therapy, Highly Active, Female, HIV-1, Humans, Middle Aged, Oligopeptides, Ritonavir, Treatment Outcome, Viral Load, antiretroviral therapy, simplification, monotherapy, atazanavir, 0303 health sciences, 3. Good health, 13. Climate action

Περιγραφή αρχείου: application/msword; application/pdf

Σύνδεσμος πρόσβασης: http://hdl.handle.net/2434/251506
https://pubmed.ncbi.nlm.nih.gov/25058680
https://pubmed.ncbi.nlm.nih.gov/25058680/
https://europepmc.org/article/MED/25058680
https://moh-it.pure.elsevier.com/en/publications/simplification-to-atazanavirritonavir-monotherapy-for-hiv-1-treat
https://www.ncbi.nlm.nih.gov/pubmed/25058680/
https://air.unimi.it/handle/2434/251506

Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results

Συγγραφείς: Castagna, A., Spagnuolo, V., Galli, Lavinia Maddalena, Vinci, C., Nozza, S., Carini, Elettra, Monforte, A. D., Montella, Francesco, Antinori, Armando, Di Biagio, Anna, Rusconi, S., Lazzarin, A., Viscoli, C., Parisini, A., Prinapori, R., Mazzotta, F., Lo Caputo, S., Di Pietro, Maria Luisa, D'Arminio-Monforte, A., Tincati, C., Bini, T., Merlini, E., Puoti, M., Moioli, M., Montella, M., Di Sora, Fiorella, Ammassari, A., Ottou, S., Cauda, Roberto, Di Giambenedetto, Simona, Galli, M., Franzetti, M., Rizzardini, G., Capetti, A., Cossarini, F., Gianotti, N., Mussini, C., Guaraldi, G., Galli L., Carini E., Montella F., Antinori A. (ORCID:0000-0002-6019-2417), Di Biagio A., Di Pietro M. (ORCID:0000-0002-3893-8788), Di Sora F., Cauda R. (ORCID:0000-0002-1498-4229), Di Giambenedetto S. (ORCID:0000-0001-6990-5076)

Όροι ευρετηρίου: Atazanavir/ritonavir, HIV, Nucleos(t)ide reverse transcriptase inhibitors toxicity, Protease inhibitor monotherapy, Simplification, Virological suppression, Adult, Anti-HIV Agents, Antiretroviral Therapy, Highly Active, Atazanavir Sulfate, Drug-Related Side Effects and Adverse Reactions, Female, HIV Infections, HIV-1, Humans, Male, Middle Aged, Oligopeptides, Pyridines, Ritonavir, Treatment Outcome, Viral Load, Settore MED/17 - MALATTIE INFETTIVE, info:eu-repo/semantics/article

Σύνδεσμος: http://hdl.handle.net/10807/193897
info:eu-repo/semantics/altIdentifier/pmid/25058680
info:eu-repo/semantics/altIdentifier/wos/WOS:000342231900010
volume:28
issue:15
firstpage:2269
lastpage:2279
numberofpages:11
issueyear:2014
journal:AIDS